Top 10 MDMA Papers

This trial tests MDMA research under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA research performs when tested under more structured clinical conditions. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

In the first randomised controlled pilot trial, MDMA-assisted psychotherapy produced greater reductions in Clinician-Administered PTSD Scale scores than placebo in participants with chronic, treatment‑resistant post‑traumatic stress disorder. There were no drug‑related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases, suggesting MDMA may be a safe and effective adjunct to psychotherapy in refractory PTSD. For readers, the value is not just the result but the study design: it shows how MDMA research performs when tested under more structured clinical conditions.

The seminal paper (1986) introduces the classification 'entactogens' for MDMA and compounds with similar psychopharmacological action. It adds a concrete angle on MDMA research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

This double-blind, placebo-controlled study investigated the physiological and psychological effects of a typical recreational dose of MDMA in drug-naïve volunteers. Results confirm MDMA’s distinct ‘entactogenic’ profile of enhanced mood and emotional sensitivity, though significant increases in blood pressure were observed, highlighting potential cardiovascular risks. It adds a concrete angle on MDMA research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

This trial tests MDMA research under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA research performs when tested under more structured clinical conditions. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

The open-label study is a summary report of the first people administered MDMA in a clinical setting. The data is limited to phenomenological descriptions obtained from therapist observations and subject experiences before, during, and after the sessions. It adds a concrete angle on MDMA research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

This trial tests MDMA research under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA research performs when tested under more structured clinical conditions. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

This trial tests MDMA research under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA research performs when tested under more structured clinical conditions. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

This paper helped define the clinical evidence for MDMA-assisted therapy for PTSD, including what benefits appear durable and what still needs careful testing. It also shows why therapy structure, follow-up, and participant selection matter as much as the acute drug session. It adds a concrete angle on MDMA research, helping readers understand the topic through evidence rather than broad claims alone. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.

This trial tests MDMA research under more rigorous clinical conditions, moving the question beyond early pilot evidence. It helps readers see whether the approach can hold up when protocols are more standardised, outcomes are clearer, and follow-up becomes harder to ignore. For readers, the value is not just the result but the study design: it shows how MDMA research performs when tested under more structured clinical conditions. Together with the other papers here, it helps separate what is distinctive about MDMA research from claims that apply to psychedelics more broadly.